A Multicentric Phase 2 Study of Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-MUTATED Acute Myeloid Leukemia
Latest Information Update: 09 Jan 2023
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms AML2521
- 13 Dec 2022 Results (n=9) characterizing a series of NPM1-Mutated Acute Myeloid Leukemia pts in molecular failure who received VEN-AZA as bridge-to-transplant treatment strategy presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Mar 2022 Status changed from not yet recruiting to recruiting.
- 31 Dec 2021 Planned End Date changed from 1 Sep 2024 to 1 Jan 2025.